Objective: We used cardiac MRI (CMR) in patients with left ventricular (LV) dysfunction related to remote myocardial infarction (MI) to test the hypothesis that bone marrow progenitor cell injection causes functional recovery of scarred myocardium and reverse remodeling.
I n a series of detailed preclinical porcine studies, we have demonstrated that transcatheter, intramyocardial injection of bone marrow-derived progenitor cells to chronically scarred myocardium is safe and improves left ventricular (LV) regional function, reduces scar size, and creates reverse remodeling. 1 A therapy that leads to reverse remodeling in chronically scarred human hearts would be precedent-setting and predicted to have favorable clinical benefits for patients. Using various imaging modalities, a growing number of clinical trials of intramyocardial bone marrow cell injections in patients with chronic ischemic heart failure have shown improved regional function; however, these improvements in regional contractility have only translated to modest global functional changes. 2, 3 Furthermore, the relationship of improved regional contractility and reverse remodeling has not been investigated. Here, we tested the hypothesis that intramyocardial injection of bone marrow-derived stem cells into humans with chronically scarred myocardium causes functional restoration followed by reverse remodeling. The data here derive from the phase I pilot of the Transendocar- Cine CMR demonstrated a decrease in end diastolic volume (EDV) (Pϭ0.033) and a trend toward decreased end systolic volume (ESV) (Pϭ0.058) ( Figure 1 and Online Figure II ). Reductions in chamber volumes were significant at 6 and 12 months compared with baseline for ESV (Pϭ0.022 and Pϭ0.023, respectively) and EDV (Pϭ0.009 and Pϭ0.014, respectively). Ejection fraction (EF) and LV mass did not change (PϭNS). A strong correlation between the changes in EDV and ESV (r 2 ϭ0.87, Pϭ0.002) demonstrates parallel decreases in chamber volumes. MI size evaluated by delayed myocardial hyperenhancement decreased by 18.3Ϯ8.3% (PϽ0.05; Figure 1D and Online Figure I ).
Peak Eulerian circumferential strain (Ecc), a measure of regional contractility calculated from tagged CMR images, showed improved regional function of the infarct zone (IZ) (Pϭ0.039) that restored function to the level of the border zone ( Figures 1 and 2) . The IZ improvements were evident as early as 3 months and persisted at 6 and 12 months compared with baseline (Pϭ0.02, Pϭ0.013, and Pϭ0.029, respectively), and strongly correlated with the changes in EDV (r 2 ϭ0.69, Pϭ0.04) and ESV (r 2 ϭ0.83, Pϭ0.01) ( Figure 2 ). Regional function in border and remote zones did not change (PϭNS).
Discussion
Here, we show that transcatheter, intramyocardial injection of autologous bone marrow preparations in patients with chronic ischemic cardiomyopathy is well-tolerated and produces functional recovery in scarred myocardium and reverse remodeling of the LV chamber. Importantly, the functional recovery is evident at 3 months following injection and precedes reverse remodeling. Because all patients had documented MI and were previously revascularized, these findings support myocardial regeneration and mirror the phenotype observed in porcine models of chronic ischemic cardiomyopathy. 1, 5 The present findings have several major implications. First, we have established that bone marrow-derived cell therapy clearly can enable reverse remodeling of dilated hearts, a phenotypic change that would be expected to have positive Tagged harmonic phase CMR strain maps show significantly depressed regional function by peak Ecc at baseline in IZ (white arrows) (D). Red/white indicates weak contractility (more positive Ecc) and green/blue indicates vigorous contractility (more negative Ecc) in harmonic phase strain maps. E and F, At 3 months after cell injection, the IZ contractility has improved (less red/white, more green/blue) (E) and by 12 months is contracting similar to the border zone (mostly green/blue) (F). G through I, ESV remains relatively stable between baseline (G) and 3 months (H); however, at 1 year, reverse remodeling is present (I). J and K, Changes in peak Ecc of the IZ had a strong correlation with the changes in EDV (J) and ESV (K) at 12 months compared with baseline (difference in peak Ecc between baseline and 1 year versus difference in normalized EDV and ESV, respectively). L, Decreases in EDV and ESV strongly correlate with each other, indicating parallel decreases in chamber sizes contributes to unchanging EF after bone marrow stem cell injections.
clinical implications. Second, the reverse remodeling caused substantial parallel declines in systolic and diastolic volumes, so that an EF increase was obscured; accordingly, this strongly suggests that EF is not a good primary end point for assessing responses to cell therapy in dilated hearts and that chamber size, MI size, or regional function is more likely to reflect a favorable outcome. Finally, these data strongly indicate that a high-resolution imaging tool such as MRI, capable of detecting the latter outcomes, is necessary for trials of cardiac regeneration. Although there is enormous enthusiasm for the possibility of repair of ischemic cardiomyopathy with cell-based therapy, mechanisms and manifestations of this strategy remain highly controversial. To address this, we phenotyped patients using cardiac MRI, which is recognized as the "reference standard" for quantitative assessment of LV function and has been shown to be the most accurate and reproducible imaging modality to assess global and regional LV function. 6, 7 Regional functional improvements (peak Ecc) of the infarct territory were calculated by harmonic phase MRI, arguably the most accurate noninvasive analytic imaging modality to measure regional strain. 8, 9 The early improvements in regional contractility of a treated infarct predicted later reverse remodeling. Regional strain of the infarct territory improved as early as 3 months following cell injection, which persisted at 6 months and 1 year (Figure 1 ). The reduction in chamber volumes was not evident until 6 months, and the correlation with improved regional strain was not apparent until 6 months and continued at 1 year (Figure 2 ). This suggests that the first manifestation of bone marrow cell therapy on the heart is improved regional function that later contributes to reverse remodeling. As a corollary to this finding, infarct size was reduced by 3 months after treatment.
Preclinical studies of bone marrow cell therapy for ischemic heart disease have demonstrated improved EF, but this has not translated to early phase studies in humans. We show a strong parallel decrease in both EDV and ESV (r 2 ϭ0.87, Pϭ0.002) 12 months after treatment. Indeed, this finding strongly suggests that EF may not be a good outcome measure for studies of cell therapy for remodeled ventricles. Importantly, both LV size and infarct size are important clinical indicators of outcome in patients with ischemic cardiomyopathy, 10 and the results here highlight a highly adaptive response to cell therapy, even in the absence of a net increase in EF.
This study lacks the power to determine superiority between mesenchymal stem cells or whole bone marrow and does not have a placebo comparison group. Although only 4 patients had longitudinal assessment of scar size (attributable to artifact distortion in delayed enhancement images due to the presence of implantable cardioverter defibrillators in some patients), MI size was reduced in each of these subjects. Each of these limitations will be definitively addressed in the ongoing TAC-HFT and POSEIDON trials, which together will treat 90 patients in placebo-controlled, blinded fashion.
In conclusion, MRI provides a unique opportunity to image the in vivo structural and functional changes after bone marrow stem cell therapy for the heart. Our data suggest human autologous bone marrow progenitor cells increase regional contractility of injected myocardial scar tissue within 3 months of treatment, and these functional changes are associated with later reverse remodeling. These findings strongly support ongoing clinical investigation of cell-based therapy for cardiomyopathy and support the use of regional function and chamber size as important end points. 
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Novelty and Significance
What Is Known?
• Catheter-based bone marrow progenitor cell injections improve cardiac function and reduce scar burden in large animal models of ischemic cardiomyopathy. • Using various imaging modalities, early human studies of bone marrow progenitor cell therapy for ischemic cardiomyopathy have shown improved regional function.
What New Information Does This Article Contribute?
• Durable reverse remodeling results from cell-based therapy for healed myocardial infarction/chronic ischemic cardiomyopathy. • Intramyocardial injections of bone marrow progenitor cells to infarct and border zones of humans with ischemic cardiomyopathy improve regional function of the scar within 3 months of therapy, and this improved regional function predicts subsequent reductions in left ventricular chamber volumes.
• End points for cell-based therapy should focus on chamber dimensions and regional function using reliable and reproducible imaging modalities, such as cardiac MRI.
Early clinical trials have shown the capacity of intramyocardial injections of bone marrow-derived progenitor cells to improve regional function with modest improvements in ejection fraction. We used cardiac MRI to phenotype the in vivo changes of the left ventricle following catheter-based intramyocardial injections of bone marrow progenitor cells. We show improved regional function of scarred myocardium within 3 months of therapy, and this predicts later reverse remodeling. For the first time, we show that this therapy can improve diastolic volumes and parallel decreases in both end systolic and end diastolic volume contribute to the lack of overall improvements in ejection fraction.
